Battery Malfunction of a Leadless Cardiac Pacemaker
Worrisome Single-Center Experience
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Leadless cardiac pacemaker (LCP) therapy has been established clinically as a feasible and safe alternative to conventional transvenous pacemaker therapy for patients with an indication for single-chamber right-ventricular pacing.1–3 However, reports on loss of telemetry and pacing output because of abrupt battery failure called the safety of 1 of the 2 commercially available systems seriously into question. The initial battery advisory with the Nanostim LCP was issued in October 2016 by the manufacturer, who instantly called a global stop to Nanostim implants. To this day, similar battery issues have not been described for the Micra transcatheter pacing system. Therefore, we thought to analyze the long-term pacemaker performance and rate of battery malfunction of the Nanostim LCP in our patient population.
This prospective observational single-center study included all consecutive patients implanted with the Nanostim LCP at our institution between November 2013 and July 2016. Patients were implanted at an early (until April 2014) and late (from December 2015) phase according to the legal implantation restrictions in Europe. Device follow-up assessments were performed predischarge, at 3 and 6 months postimplantation, and then regularly every 6 months. At each outpatient visit, LCP …